Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

Welcome to the Cyprus Journal of Medical Sciences, a distinguished publication dedicated to the advancement of medical knowledge and research. Published by GALENOS PUBL HOUSE, this journal endeavors to uphold the highest standards of scientific inquiry in the medical field. With its ISSN 2149-7893 and E-ISSN 2536-507X, the journal serves as an essential resource for researchers, healthcare professionals, and students seeking to stay abreast of innovative findings and clinical practices. Although currently not listed under Open Access, this journal prioritizes rigorous peer review and the dissemination of impactful research aimed at driving improvements in medical science. The journal welcomes submissions that cover diverse areas within the medical realm, contributing to a more profound understanding of healthcare challenges and solutions. Join us in exploring the frontiers of medical sciences and contributing to a healthier future.

Current Fungal Infection Reports is an essential academic journal dedicated to the rapidly evolving field of mycology, specifically focusing on the diagnosis, treatment, and epidemiology of fungal infections. Published by Springer, this journal aims to provide a comprehensive platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings and insights into the complexities surrounding fungal diseases. With an ISSN of 1936-3761 and an E-ISSN of 1936-377X, the journal is recognized in the Q3 category for Infectious Diseases as of 2023 and holds a Scopus rank of #199 out of 344 in its field, showcasing its growing influence. Although not currently open access, Current Fungal Infection Reports remains an important resource for those wishing to stay updated on key developments and trends within this critical area of global health. Through its commitment to advancing knowledge and fostering academic exchange, the journal plays a crucial role in combating the challenges posed by fungal infections, making it a must-read for anyone involved in infectious disease research and treatment.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

European Respiratory Review is a prestigious peer-reviewed journal published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, specializing in the dynamic field of pulmonary and respiratory medicine. With an impact factor that places it among the top quartile journals in its category (Q1), as indicated by its impressive Scopus rank of #7 out of 155, it serves as a critical platform for disseminating high-quality research and innovative reviews in the field. As an Open Access journal since 2005, it ensures that cutting-edge findings are readily available to a global audience, promoting greater transparency and collaboration within the academic community. Published from Switzerland, European Respiratory Review covers a broad spectrum of topics from clinical advancements to emerging trends, making it an essential resource for researchers, healthcare professionals, and students committed to advancing respiratory health. The journal's history, dating back to 1992, reflects a steadfast commitment to fostering scholarly exchange and driving forward the frontiers of knowledge within respiratory medicine.

Asian Pacific Journal of Tropical Medicine, published by Wolters Kluwer Medknow Publications, stands at the forefront of research in the field of tropical medicine, contributing significantly to the global understanding of health issues prevalent in the Asian Pacific region. With an ISSN of 1995-7645 and an E-ISSN of 2352-4146, this esteemed journal has been an Open Access platform since 2011, ensuring that vital research is accessible to a broad audience. The journal boasts a commendable Scopus rank of 131 out of 636 in the General Medicine category, placing it in the 79th percentile and recognizing its influential contributions to the discipline. Based in Mumbai, India, the journal spans converged years from 2010 to 2024 and is categorized in the Q3 quartile for miscellaneous medicine as of 2023. Researchers, professionals, and students can leverage this journal to stay abreast of the latest findings and developments in tropical medicine, making it an indispensable resource in their academic and professional pursuits.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.